Cellanyx
Commercializing a first-in-class machine learning-powered biopsy-on-a-chip platform for precision cancer testing and personalized therapies.
- Stage Full Product Ready
- Industry Biotechnology
- Location Boston, MA, USA
- Currency USD
- Founded January 2013
- Employees 8
- Incorporation Type LLC
- Website cellanyx.com
Company Summary
The absence of reliable predictive diagnostic tests has emerged as a major barrier to personalized medicine in cancer. Cellanyx’s phenotypic platform directly assesses the dynamic behavior of live biopsy cells, uniquely quantifying the hallmarks of cancer and cancer aggressiveness such as cell movement and protein dynamics.
Team
-
Ashok ChanderChief Executive Officer, Founder
SB, MIT; PhD, Columbia University
-
Jonathan VarsanikVP Engineering
SB, MIT; PhD, MIT
-
Michael ManakVP Research & Development
PhD, University of Florida; Post Doctoral Fellow, Harvard Medical School
-
VP of Commercialization
BS, UMN
-
Marketing Lead
BS, University of California, San Diego; MS, Columbia University
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.